Michael Thiele

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 4

Top Topics

Clinical Evaluation

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Alejandro A Puchol Tarazona, Alexander Schinagl, Irina Mirkina, Gregor Rossmueller, Randolf J Kerschbaumer, Friedmund Bachmann, Michael Thiele
Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer. Molecular cancer therapeutics (2024)
Alejandro A Puchol Tarazona, Alexander Schinagl, Irina Mirkina, Gregor Rossmueller, Randolf J Kerschbaumer, Friedmund Bachmann, Michael Thiele
Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer. Molecular cancer therapeutics (2024)
Gregor Rossmueller, Irina Mirkina, Barbara Maurer, Verena Hoeld, Julia Mayer, Michael Thiele, Randolf J Kerschbaumer, Alexander Schinagl
Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic. Molecular cancer therapeutics (2023)
Alexander Schinagl, Randolf J Kerschbaumer, Nicolas Sabarth, Patrice Douillard, Peter Scholz, Dirk Voelkel, Julia C Hollerweger, Peter Goettig, Hans Brandstetter, Friedrich Scheiflinger, Michael Thiele
Role of the Cysteine 81 Residue of Macrophage Migration Inhibitory Factor as a Molecular Redox Switch. Biochemistry 57 (9) (2018)